Barcode Enabled Antigen Mapping (BEAM) screens multiple antigens against thousands of B- or T-cells to identify novel and rare antigen-specific repertoires

PLEASANTON, Calif., Nov. 9, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery. Built on top of 10x's industry-leading Chromium Single Cell Immune Profiling product, BEAM's proprietary antigen screening approach is fast and robust, delivering hundreds of antigen-receptor pairs with single cell gene expression. The combination of robust screening; simple, fast, and validated workflows; and, comprehensive interrogation of each cell has the potential to greatly accelerate and improve therapeutic discovery. 

10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

"As nearly every disease involves the immune system in some way—whether it's an infectious disease, autoimmunity, cancer, or inflammation—it's critical to have a fundamental understanding of the immune response in order to fully understand the disease," said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. "BEAM enables researchers to gain more insight than ever into the immune system's basic mechanisms at high throughput and resolution, which can help translate the power of the natural immune response into the next wave of powerful, life-saving therapeutics."

It remains difficult and costly to match antigens of interest with specific B- or T- cell receptors. Conventional methods are slow, laborious and lack full-length paired V(D)J receptor sequences. BEAM solves these challenges by offering ready-to-use kitted reagents for uniquely tagging and multiplexing antigens of interest. BEAM's protocol is fully optimized, takes only a week to run and is paired with an easy-to-use software that identifies and matches putative antigens with their cognate full-length paired V(D)J receptors. The result is a comprehensive solution to interrogate the genetics and binding specificities of thousands of individual antigen-specific B- and T- cells, providing an expansive view of the underlying immune repertoires against pathogens and diseases.

"BEAM technology will greatly advance our understanding of infectious disease biology and will speed the discovery of exceptionally rare monoclonal antibodies with unique, therapeutically desirable specificities," said Bryan Briney, Assistant Professor at Scripps Research Institute. "The BEAM workflow generates rich and powerful data that helps our understanding of variant-resistant immunity and will play a key role in the design and development of durable vaccines."

BEAM is the sixth major product launch from 10x Genomics this year, demonstrating the velocity and strength of the company's R&D pipeline. BEAM is now available for pre-order and is expected to begin shipping in December 2022. For more information, please visit https://www.10xgenomics.com/products/single-cell-barcode-enabled-antigen-mapping.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 4,100 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,600 issued patents and patent applications.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, capabilities and adoption. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19 pandemic. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Disclosure Information

10x Genomics uses filings with the SEC, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Media Contact:
media@10xgenomics.com

Investor Relations Contact:
investors@10xgenomics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-beam-to-improve-and-streamline-antibody-and-t-cell-receptor-discovery-301673594.html

SOURCE 10x Genomics, Inc.

Copyright 2022 PR Newswire

10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more 10x Genomics Charts.
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more 10x Genomics Charts.